The Charles T. Campbell Eye Microbiology Lab
UPMC | University of Pittsburgh Medical CenterUniversity of Pittsburgh Schools of the Health Sciences
HomeAbout UsLab Diagnostic TestingAntibiotic SusceptibilityAntimicrobial TherapyCurrent ResearchContact Us

2003 OMIG, Abstract 21

OMIG Main Page | 2003 Abstracts | < Previous | Next>

The Threat of Atypical Mycobacteria in Ophthalmology
Barry A. Schlech1, David W. Stroman1, Eduardo Alfonso2, Kirk WiIheImus3 and Robert L. Abshire1.
1AIcon Research, Ltd., Fart Worth, Texas; 2Bascom Palmer Eye Institute, University of Miami, Miami, Florida,
3Department of Ophthalmology, Baylor College of Medicine, Houston, Texas

Purpose: To assess the relative pathology of atypical (non-tuberculous) mycobacteria in ocular infections and the in vitro antibacterial activity of newer antibiotics against these organisms.
Methods: Comparison of the susceptibility to fluoroquinolones of a variety of atypical (non-tuberculous) Mycobacterium species, taxonomic and growth characteristics, as well as incidence in ocular infections.
Results: Of the fluoroquinolones, moxifloxacin had one of the lowest MICs against Mycobacterium fortuitum, M. chelonae and M. avium. The peculiar incidence of atypical mycobacteria in ocular post-LASIK infections is balanced by the potential of 4th generation fluoroquinolones to treat and prevent these infections.
Conclusions: The fluoroquinolone family of antibiotics, and moxifloxacin in particular, has properties favorable for the treatment and prevention of ocular infections caused by atypical (non-tuberculous) mycobacteria, including M. chelonae and M. fortuitum.

OMIG Main Page | 2003 Abstracts | < Previous | Next>

Top of Page

Web Site Terms of Use | E-mail Terms of Use | Medical Advice Disclaimer
UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences | Contact UPMC